TMDX Stock Analysis: TransMedics | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 2.462m USD | 12M Return: -42.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 72.2M
Qual. Beats: -2
Rev. Trend: 96.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
TransMedics Group, Inc. (NASDAQ: TMDX) is a commercial-stage medical technology company that focuses on transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The companys core product is the Organ Care System (OCS), a portable platform that perfuses, optimizes, and monitors donor organs outside the human body under near-physiologic conditions, with dedicated modules for lungs, hearts, and livers. Beyond its hardware, TransMedics operates a national OCS program that provides turnkey organ retrieval, management, and logistics services, including aviation and ground transportation, making it both a medical device manufacturer and a transplant logistics provider. Founded in 1998 and headquartered in Andover, Massachusetts, the company went public in May 2019 and sits within the Health Care Equipment sub-industry, a sector that supplies hospitals and surgical centers with specialized capital equipment used in complex procedures.
- OCS Lung and Heart shipment volumes accelerate revenue growth
- National OCS Program expands outsourced organ retrieval contracts
- Aviation logistics services add high-margin recurring revenue stream
| Net Income: 171.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 18.10 > 1.0 |
| NWC/Revenue: 82.93% < 20% (prev 92.23%; Δ -9.30% < -1%) |
| CFO/TA 0.15 > 3% & CFO 220.2m > Net Income 171.9m |
| Net Debt (751.9m) to EBITDA (139.7m): 5.38 < 3 |
| Current Ratio: 6.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.2m) vs 12m ago -9.32% < -2% |
| Gross Margin: 59.09% > 18% (prev 59.45%; Δ -0.36% > 0.5%) |
| Asset Turnover: 55.97% > 50% (prev 58.29%; Δ -2.33% > 0%) |
| Interest Coverage Ratio: 6.11 > 6 (EBIT TTM 106.8m / Interest Expense TTM 17.5m) |
| A: 0.37 (Total Current Assets 619.3m - Total Current Liabilities 91.9m) / Total Assets 1.43b |
| B: -0.19 (Retained Earnings -270.6m / Total Assets 1.43b) |
| C: 0.09 (EBIT TTM 106.8m / Avg Total Assets 1.14b) |
| D: 0.53 (Book Value of Equity 494.0m / Total Liabilities 940.8m) |
| Altman-Z'' = 2.98 = A |
| DSRI: 0.49 (Receivables 90.7m/142.0m, Revenue 635.9m/488.2m) |
| GMI: 1.01 (GM 59.45% / 59.09%) |
| AQI: 4.66 (AQ_t 0.08 / AQ_t-1 0.02) |
| SGI: 1.30 (Revenue 635.9m / 488.2m) |
| TATA: -0.03 (NI 171.9m - CFO 220.2m) / TA 1.43b) |
| Beneish M = -1.06 (Cap -4..+1) = D |
As of July 11, 2026, the stock is trading at USD 71.23 with a total of 427,243 shares traded. Over the past week, the price has changed by +3.44%, over one month by -4.73%, over three months by -37.52% and over the past year by -42.92%.
Current recommended Stop Loss: 66.20 (which is 7.1% or 1.2 ATR below the current price).
TransMedics has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy TMDX.
- StrongBuy: 5
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 116.2 | 63.2% |
P/E Trailing = 16.2998
P/E Forward = 36.4964
P/S = 3.8714
P/B = 5.0504
Revenue TTM = 635.9m USD
EBIT TTM = 106.8m USD
EBITDA TTM = 139.7m USD
Long Term Debt = 498.2m USD (from longTermDebt, last quarter)
Short Term Debt = 18.5m USD (from shortTermDebt, last quarter)
Debt = 1.21b USD (from shortLongTermDebtTotal, last quarter) + Leases 350.2m
Net Debt = 751.9m USD (calculated: Debt 1.21b - CCE 461.7m)
Enterprise Value = 3.21b USD (2.46b + Debt 1.21b - CCE 461.7m)
Interest Coverage Ratio = 6.11 (Ebit TTM 106.8m / Interest Expense TTM 17.5m)
EV/FCF = 21.23x (Enterprise Value 3.21b / FCF TTM 151.4m)
FCF Yield = 4.71% (FCF TTM 151.4m / Enterprise Value 3.21b)
FCF Margin = 23.80% (FCF TTM 151.4m / Revenue TTM 635.9m)
Net Margin = 27.04% (Net Income TTM 171.9m / Revenue TTM 635.9m)
Gross Margin = 59.09% ((Revenue TTM 635.9m - Cost of Revenue TTM 260.2m) / Revenue TTM)
Gross Margin QoQ = 58.16% (prev 58.11%)
Tobins Q-Ratio = 2.24 (Enterprise Value 3.21b / Total Assets 1.43b)
Interest Expense / Debt = 1.44% (Interest Expense 17.5m / Debt 1.21b)
Taxrate = 13.79% (1.17m / 8.48m)
NOPAT = 92.1m (EBIT 106.8m * (1 - 13.79%))
Current Ratio = 6.74 (Total Current Assets 619.3m / Total Current Liabilities 91.9m)
Debt / Equity = 2.46 (Debt 1.21b / totalStockholderEquity, last quarter 494.0m)
Debt / EBITDA = 5.38 (Net Debt 751.9m / EBITDA 139.7m)
Debt / FCF = 4.97 (Net Debt 751.9m / FCF TTM 151.4m)
Total Stockholder Equity = 410.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.13% (Net Income 171.9m / Total Assets 1.43b)
RoE = 41.92% (Net Income TTM 171.9m / Total Stockholder Equity 410.1m)
RoCE = 11.76% (EBIT 106.8m / Capital Employed (Equity 410.1m + L.T.Debt 498.2m))
RoIC = 6.93% (NOPAT 92.1m / Invested Capital 1.33b)
WACC = 6.93% (E(2.46b)/V(3.68b) * Re(9.74%) + D(1.21b)/V(3.68b) * Rd(1.44%) * (1-Tc(0.14)))
Discount Rate = 9.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 2.58%
[DCF] Terminal Value 75.44% ; FCFF base≈151.4m ; Y1≈152.0m ; Y5≈161.0m
[DCF] Fair Price = 50.70 (EV 2.50b - Net Debt 751.9m = Equity 1.75b / Shares 34.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.01 | # QB: -2
Revenue Correlation: 96.77 | Revenue CAGR: 65.56% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.52 | Chg30d=-7.84% | Revisions=-40% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=-4.02% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=-8.30% | Revisions=-40% | GrowthEPS=-27.3% | GrowthRev=+21.1%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=-11.43% | Revisions=-40% | GrowthEPS=+59.8% | GrowthRev=+18.4%
[Analyst] Revisions Ratio: -55% (up=1, down=7)